# PharmAbcine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pharmabcine

- Industry: Biotechnology
- Headquarters: Daejeon, South Korea
- Website: www.pharmabcine.com
- Total disclosed funding: $25M
- Latest round: Series G (Feb 1, 2018)
- Investors on record: 17

## About

Based in Daejeon, South Korea, and founded in 2008, PharmAbcine is a specialized biotech company that develops fully human therapeutic monoclonal antibodies (mAb) using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases. It also offers antibody panning services. In December 2009, the company established an R&D Center. The company was nominated as Korea Brain Power Company in 2015. In November 2018, the company was listed on KOSDAQ. In 2020, the company established a branch office in the United States.

The core technologies of the company include human antibody libraries, antibody development, and bispecific antibody engineering. These technologies provide therapeutic antibodies for a wide spectrum of indications in oncology, immuno-oncology, ophthalmology, and pulmonology. The company focuses on the development of novel antibody therapeutics. The pipelines of the company include Olinvacimab, PMC-309, PMC-402 and PMC-403.

## Funding rounds

- Series G, Feb 1, 2018, $3.7M — SBI Investment Korea
- Series F, Nov 30, 2017, $3.7M — Meritz Securities, Shinhan Venture Investment
- Series E, Oct 16, 2017, $1.7M — KB Securities, DB Securities
- Series C, Mar 31, 2015, $1.8M — IMM Investment
- Series B, Jun 12, 2013, $8.8M — Novartis Venture Fund, KB Investment, Yuanta Investment, Daesung Private Equity, Daekyo Investment, Mirae Asset Venture Investment, Wooshin Venture Capital, Hanwha Investment & Securities
- Series A, Sep 3, 2009, $4.9M — OrbiMed Advisors, Novartis Venture Fund, Yuanta Investment, Saehan Venture Capital, Green Cross Holdings

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B
- Yuanta Investment (https://capitalatlas.ai/funds/yuanta-investment) — Series A, Series B
- Saehan Venture Capital (https://capitalatlas.ai/funds/saehan-venture-capital) — Series A
- Green Cross Holdings — Series A
- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series B
- Daesung Private Equity (https://capitalatlas.ai/funds/daesung-private-equity) — Series B
- Daekyo Investment (https://capitalatlas.ai/funds/daekyo-investment) — Series B
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series B
- Wooshin Venture Capital (https://capitalatlas.ai/funds/wooshin-venture-capital) — Series B
- Hanwha Investment & Securities (https://capitalatlas.ai/funds/hanwha-investment-securities) — Series B
- IMM Investment (https://capitalatlas.ai/funds/imm-investment) — Series C
- KB Securities (https://capitalatlas.ai/funds/kb-securities) — Series E
- DB Securities (https://capitalatlas.ai/funds/db-securities) — Series E
- Meritz Securities — Series F
- Shinhan Venture Investment (https://capitalatlas.ai/funds/shinhan-venture-investment) — Series F
- SBI Investment Korea (https://capitalatlas.ai/funds/sbi-investment-korea) — Series G